Collplant biotechnologies announces first quarter financial results for 2023 and provides corporate update

Strong positive sales trajectory for rhcollagen based products continued advancement of strategic collaboration with abbvie to develop dermal and soft tissue filler products using collplant's recombinant human collagen   readying sites to begin large-animal study planned in the second half of 2023 to advance 3d bioprinted regenerative breast implant program conference call to be held on may 24, 2023 at 10:00 am u.s. et; dial-in information herein rehovot, israel , may 24, 2023 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the first quarter ended march 31, 2023, and provided a corporate update on its programs. "recently, we announced a collaborative agreement with stratasys, a world-leader in 3d printing as well as completed the first large-animal study for our 3d bioprinted regenerative breast implants," said collplant's chief executive officer, yehiel tal.
CLGN Ratings Summary
CLGN Quant Ranking